Lumvoa™ veligrotug-vvze 500mg injection

Dosing Table

The chart reflects vial quantities used to achieve the recommended 10 mg/kg dose of Lumvoa and should not be interpreted as a recommendation for treatment of any particular patient.

All patient care, treatment, and dosing decisions remain the responsibility of the treating healthcare provider.

Lumvoa dosing should be calculated using the patient's actual body weight and in accordance with the current Prescribing Information. Please refer to the current Full Prescribing Information for complete dosing, preparation, administration, and safety information.

Dose Preparation for 10 mg/kg Dose[1]

The recommended dosage of Lumvoa is 10 mg/kg administered by intravenous (IV) infusion every 3 weeks for a total of 5 infusions.

Dosage Calculation

For weight conversion purposes, 1 kilogram (kg) is equivalent to 2.2 pounds (lbs).

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
529	240	2400	5	48.0
527	239	2390	5	47.8
525	238	2380	5	47.6
522	237	2370	5	47.4
520	236	2360	5	47.2
518	235	2350	5	47.0
516	234	2340	5	46.8
514	233	2330	5	46.6
511	232	2320	5	46.4
509	231	2310	5	46.2
507	230	2300	5	46.0
505	229	2290	5	45.8
503	228	2280	5	45.6
500	227	2270	5	45.4
498	226	2260	5	45.2
496	225	2250	5	45.0
494	224	2240	5	44.8
492	223	2230	5	44.6
489	222	2220	5	44.4
487	221	2210	5	44.2

Reference: 1. Lumvoa™ (veligrotug-vvze). Prescribing Information. Viridian Therapeutics, Inc; 2026.

Lumvoa™
veligrotug-vvze 500mg injection

Dosing Table

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
485	220	2200	5	44.0
483	219	2190	5	43.8
481	218	2180	5	43.6
478	217	2170	5	43.4
476	216	2160	5	43.2
474	215	2150	5	43.0
472	214	2140	5	42.8
470	213	2130	5	42.6
467	212	2120	5	42.4
465	211	2110	5	42.2
463	210	2100	5	42.0
461	209	2090	5	41.8
459	208	2080	5	41.6
456	207	2070	5	41.4
454	206	2060	5	41.2
452	205	2050	5	41.0
450	204	2040	5	40.8
448	203	2030	5	40.6
445	202	2020	5	40.4
443	201	2010	5	40.2
441	200	2000	4	40.0
439	199	1990	4	39.8
437	198	1980	4	39.6
434	197	1970	4	39.4
432	196	1960	4	39.2
430	195	1950	4	39.0
428	194	1940	4	38.8
425	193	1930	4	38.6
423	192	1920	4	38.4
421	191	1910	4	38.2
419	190	1900	4	38.0
417	189	1890	4	37.8
414	188	1880	4	37.6
412	187	1870	4	37.4
410	186	1860	4	37.2
408	185	1850	4	37.0
406	184	1840	4	36.8

Lumvoa™
veligrotug-vvze 500mg injection

Dosing Table

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
403	183	1830	4	36.6
401	182	1820	4	36.4
399	181	1810	4	36.2
397	180	1800	4	36.0
395	179	1790	4	35.8
392	178	1780	4	35.6
390	177	1770	4	35.4
388	176	1760	4	35.2
386	175	1750	4	35.0
384	174	1740	4	34.8
381	173	1730	4	34.6
379	172	1720	4	34.4
377	171	1710	4	34.2
375	170	1700	4	34.0
373	169	1690	4	33.8
370	168	1680	4	33.6
368	167	1670	4	33.4
366	166	1660	4	33.2
364	165	1650	4	33.0
362	164	1640	4	32.8
359	163	1630	4	32.6
357	162	1620	4	32.4
355	161	1610	4	32.2
353	160	1600	4	32.0
351	159	1590	4	31.8
348	158	1580	4	31.6
346	157	1570	4	31.4
344	156	1560	4	31.2
342	155	1550	4	31.0
340	154	1540	4	30.8
337	153	1530	4	30.6
335	152	1520	4	30.4
333	151	1510	4	30.2
331	150	1500	3	30.0
328	149	1490	3	29.8
326	148	1480	3	29.6
324	147	1470	3	29.4

Lumvoa™
veligrotug-vvze 500mg injection

Dosing Table

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
322	146	1460	3	29.2
320	145	1450	3	29.0
317	144	1440	3	28.8
315	143	1430	3	28.6
313	142	1420	3	28.4
311	141	1410	3	28.2
309	140	1400	3	28.0
306	139	1390	3	27.8
304	138	1380	3	27.6
302	137	1370	3	27.4
300	136	1360	3	27.2
298	135	1350	3	27.0
295	134	1340	3	26.8
293	133	1330	3	26.6
291	132	1320	3	26.4
289	131	1310	3	26.2
287	130	1300	3	26.0
284	129	1290	3	25.8
282	128	1280	3	25.6
280	127	1270	3	25.4
278	126	1260	3	25.2
276	125	1250	3	25.0
273	124	1240	3	24.8
271	123	1230	3	24.6
269	122	1220	3	24.4
267	121	1210	3	24.2
265	120	1200	3	24.0
262	119	1190	3	23.8
260	118	1180	3	23.6
258	117	1170	3	23.4
256	116	1160	3	23.2
254	115	1150	3	23.0
251	114	1140	3	22.8
249	113	1130	3	22.6
247	112	1120	3	22.4
245	111	1110	3	22.2
243	110	1100	3	22.0

Lumvoa™
veligrotug-vvze 500mg injection

Dosing Table

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
240	109	1090	3	21.8
238	108	1080	3	21.6
236	107	1070	3	21.4
234	106	1060	3	21.2
231	105	1050	3	21.0
229	104	1040	3	20.8
227	103	1030	3	20.6
225	102	1020	3	20.4
223	101	1010	3	20.2
220	100	1000	2	20.0
218	99	990	2	19.8
216	98	980	2	19.6
214	97	970	2	19.4
212	96	960	2	19.2
209	95	950	2	19.0
207	94	940	2	18.8
205	93	930	2	18.6
203	92	920	2	18.4
201	91	910	2	18.2
198	90	900	2	18.0
196	89	890	2	17.8
194	88	880	2	17.6
192	87	870	2	17.4
190	86	860	2	17.2
187	85	850	2	17.0
185	84	840	2	16.8
183	83	830	2	16.6
181	82	820	2	16.4
179	81	810	2	16.2
176	80	800	2	16.0
174	79	790	2	15.8
172	78	780	2	15.6
170	77	770	2	15.4
168	76	760	2	15.2
165	75	750	2	15.0
163	74	740	2	14.8
161	73	730	2	14.6

Lumvoa™
veligrotug-vvze 500mg injection

Dosing Table

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
159	72	720	2	14.4
157	71	710	2	14.2
154	70	700	2	14.0
152	69	690	2	13.8
150	68	680	2	13.6
148	67	670	2	13.4
146	66	660	2	13.2
143	65	650	2	13.0
141	64	640	2	12.8
139	63	630	2	12.6
137	62	620	2	12.4
134	61	610	2	12.2
132	60	600	2	12.0
130	59	590	2	11.8
128	58	580	2	11.6
126	57	570	2	11.4
123	56	560	2	11.2
121	55	550	2	11.0
119	54	540	2	10.8
117	53	530	2	10.6
115	52	520	2	10.4
112	51	510	2	10.2
110	50	500	1	10.0
108	49	490	1	9.8
106	48	480	1	9.6
104	47	470	1	9.4
101	46	460	1	9.2
99	45	450	1	9.0
97	44	440	1	8.8
95	43	430	1	8.6
93	42	420	1	8.4
90	41	410	1	8.2
88	40	400	1	8.0
86	39	390	1	7.8
84	38	380	1	7.6
82	37	370	1	7.4
79	36	360	1	7.2

Lumvoa™ veligrotug-vvze 500mg injection

Dosing Table

Patient Weight (lbs)	Patient Weight (kg)	Total Lumvoa required for a single infusion (mg)	#Vials Required	Amount (mL) of Lumvoa Drug Product solution to add (= X)
77	35	350	1	7.0
75	34	340	1	6.8
73	33	330	1	6.6
71	32	320	1	6.4
68	31	310	1	6.2
66	30	300	1	6.0

Indication: Lumvoa is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration.

Important Safety Information

Infusion Reactions: Lumvoa may cause infusion reactions. Infusion reactions have been reported in approximately 9% of patients treated with Lumvoa. Signs and symptoms of infusion-related reactions include transient increases in blood pressure, fever, chills, headache, and fatigue. Infusion reactions may occur during or soon after an infusion. Reported infusion reactions are usually mild or moderate in severity and can usually be successfully managed with corticosteroids, antihistamines, and antipyretics. In patients who experience an infusion reaction, consideration should be given to standard premedication and/or administering infusions at a slower infusion rate.

Inflammatory Bowel Disease: Lumvoa may cause an exacerbation of inflammatory bowel disease (IBD). IBD has been reported in some patients receiving insulin-like growth factor-1 receptor inhibitors without a prior diagnosis of IBD. Monitor patients for signs and symptoms of IBD, including patients without a history of IBD. If IBD is suspected, discontinue use of Lumvoa.

Hyperglycemia: Hyperglycemia or increased blood glucose may occur in patients treated with Lumvoa. In clinical trials, 12% of patients, of whom one-half had preexisting diabetes or impaired glucose tolerance, experienced hyperglycemia. Hyperglycemic events should be controlled with medications for glycemic control, if necessary. Assess patients for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with Lumvoa. Ensure patients with hyperglycemia or preexisting diabetes are under appropriate glycemic control before and while receiving Lumvoa. Continued monitoring after treatment is recommended for patients who experience hyperglycemia while on Lumvoa.

Hearing Impairment Including Hearing Loss: Lumvoa may cause severe hearing impairment including hearing loss, which in some cases may be permanent. Assess patients' hearing before, during, and after treatment with Lumvoa and consider the benefit-risk of treatment with patients.

Most Common Adverse Events: Most common adverse reactions (incidence of 5% or more) are muscle spasms, headache, hearing impairment, hyperglycemia, fatigue, diarrhea, ear discomfort, infusion-related reaction, nausea, nasopharyngitis, blood creatine phosphokinase increased, dry skin, and hypertension.

Females of Reproductive Potential: Appropriate forms of contraception should be implemented prior to initiation, during treatment, and for 6 months following the last dose of Lumvoa.

Lumvoa (500 mg) is an injection for infusion.

Please see accompanying Full **Prescribing Information**.

©2026 Viridian Therapeutics, Inc. All Rights Reserved.
US-LV-0011 07/26